Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo - PubMed (original) (raw)

Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo

J Bai et al. Mol Ther. 2000 Mar.

Free article

Abstract

The cellular entry of HIV is mediated by the specific interaction of viral envelope glycoproteins with the cell-surface marker CD4 and a chemokine receptor (CCR5 or CXCR4). Individuals with a 32-base-pair (bp) deletion in the CCR5 coding region, which results in a truncated peptide, show resistance to HIV-1 infection. This suggests that the downregulation of CCR5 expression on target cells may prevent HIV infection. Therefore, ribozymes that inhibit the CCR5 expression offer a novel approach for anti-HIV gene therapy. To assess the effect of an anti-CCR5 ribozyme (R5Rbz) on macrophage differentiation, CD34+ hematopoietic progenitor cells were transduced with a retroviral vector carrying RSRbz and allowed to differentiate in the presence of appropriate cytokines. R5Rbz-transduced CD34+ cells differentiated normally into mature macrophages that carried CD14 and CD4 surface markers, expressed the anti-CCR5 ribozyme, and showed significant resistance to viral infection upon challenge with the HIV-1 BaL strain. Using an in vivo thymopoiesis model, the effect of RSRbz on stem cell differentiation into thymocytes was evaluated by reconstituting SCID-hu mice thymic grafts with ribozyme-transduced CD34+ cells. FACS analysis of cell biopsies at 4 and 6 weeks postengraftment for HLA, CD4, and CD8 markers showed comparable levels of reconstitution and similar percentages of subpopulations of thymocytes between grafts receiving R5Rbz-transduced and control CD34+ cells. RT-PCR assays demonstrated the expression of the anti-CCR5 ribozyme in CD4+, CD8+, and CD4+/CD8+ thymocyte subsets derived from RSRbz-transduced CD34+ cells. These results indicate that anti-CCR5 ribozyme can be introduced into hematopoietic stem cells without adverse effects on their subsequent lineage-specific differentiation and maturation. The expression of anti-CCR5 ribozymes in HIV-1 target cells offers a novel gene therapy strategy to control HIV infection.

PubMed Disclaimer

Cited by

Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice.
Bennett MS, Akkina R. Bennett MS, et al. Viruses. 2013 Dec 12;5(12):3119-41. doi: 10.3390/v5123119. Viruses. 2013. PMID: 24351796 Free PMC article. Review.
Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.
Anderson JS, Walker J, Nolta JA, Bauer G. Anderson JS, et al. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):152-61. doi: 10.1097/QAI.0b013e3181b010a0. J Acquir Immune Defic Syndr. 2009. PMID: 19593160 Free PMC article.
Modeling the evolution of SIV sooty mangabey progenitor virus towards HIV-2 using humanized mice.
Schmitt K, Mohan Kumar D, Curlin J, Remling-Mulder L, Stenglein M, O'Connor S, Marx P, Akkina R. Schmitt K, et al. Virology. 2017 Oct;510:175-184. doi: 10.1016/j.virol.2017.07.005. Epub 2017 Jul 24. Virology. 2017. PMID: 28750321 Free PMC article.
Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment.
Yuan J, Wang J, Crain K, Fearns C, Kim KA, Hua KL, Gregory PD, Holmes MC, Torbett BE. Yuan J, et al. Mol Ther. 2012 Apr;20(4):849-59. doi: 10.1038/mt.2011.310. Epub 2012 Jan 24. Mol Ther. 2012. PMID: 22273578 Free PMC article.
Derivation of normal macrophages from human embryonic stem (hES) cells for applications in HIV gene therapy.
Anderson JS, Bandi S, Kaufman DS, Akkina R. Anderson JS, et al. Retrovirology. 2006 Apr 19;3:24. doi: 10.1186/1742-4690-3-24. Retrovirology. 2006. PMID: 16623949 Free PMC article.

Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo - PubMed (original) (raw)